The role of pharmacogenetics in the treatment of depression and anxiety disorders

2009 ◽  
Vol 24 (6) ◽  
pp. 277-288 ◽  
Author(s):  
Alexandra Schosser ◽  
Siegfried Kasper
Keyword(s):  
Anxiety Disorders ◽  
Depression And Anxiety ◽  
Treatment Of Depression

Gene–environment interactions in animal models of depression and anxiety

2019 ◽  
pp. 63-76
Author(s):  
Daniela Felice ◽  
Anand Gururajan ◽  
Olivia F O’Leary ◽  
John F Cryan
Keyword(s):  
Anxiety Disorders ◽  
Target Genes ◽  
Preclinical Studies ◽  
Depression And Anxiety ◽  
Complex Interactions ◽  
Gene Environment ◽  
Animal Models Of Depression ◽  
Treatment Of Depression ◽  
Candidate Target ◽  
The Individual

Depression and anxiety disorders cause the greatest global disability in terms of impact on the individual, family, and society at large. The etiology of these disorders is multifactorial and includes complex interactions between genetic and environmental risk factors. This chapter reviews preclinical studies assessing the importance of gene–environment (G×E) interaction. Specifically, we focus on G×E studies assessing the roles of the hypothalamic–pituitary–adrenal (HPA) axis, serotonergic system, GABAergic system, and brain-derived neurotrophic factor (BDNF) system. Finally, novel candidate target genes for the treatment of depression and anxiety disorders are considered.

5-HT3 receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders

2020 ◽  
Vol 18 ◽  
Author(s):  
Shvetank Bhatt ◽  
Thangaraj Devadoss ◽  
SN Manjula ◽  
Jayaraman Rajangam
Keyword(s):  
Common Mental Disorder ◽  
Stress Disorders ◽  
Depression And Anxiety ◽  
Predominant Role ◽  
Major Depressive ◽  
Anxiety Control ◽  
Treatment Of Depression ◽  
The Central Nervous System ◽  
Type 3

Background: Depression or Major depressive disorder (MDD) is prolonged condition of sadness. MDD is the most common mental disorder that affects more than 264 million people worldwide. According to monoamine hypothesis, serotonin (5-hydroxy tryptamine, 5-HT), dopamine (DA) and norepinephrine (NE) are the major neurotransmitters (NTs) involved in depression. Method: The methodology adopted for writing this review article is essentially based on the secondary literature search through systematic literature review. This review mainly focussed on the role of 5-HT3 receptor antagonists (5-HT3RA) in depression and comorbid disorder like anxiety. Results: Out of three major NTs mentioned above, serotonin has predominant role in the pathophysiology of depression. The serotonin type-3 receptors (5-HT3R) are well renowned to be expressed in the central nervous system (CNS) in regions which have significance in the vomiting reflex, perception of pain, the reward system, cognition, depression and anxiety control. The 5-HT3R is only receptor of serotonergic family that belongs to ligand gated ion channel. The 5-HT3RA inhibit the binding of serotonin to post synaptic 5-HT3R and increase its availability to other receptors like 5-HT1A, 1B and 1D as well as 5-HT2 receptors and produces anti-depressant-like effect. The 5-HT3RA also have important role in mood and stress disorders. Some of the studies have shown the effectiveness of these agents in stress disorder. Conclusion: The present article focused on the role of 5-HT3R and their antagonists in the treatment of depression and anxiety. Further studies are warranted to prove their efficacy with respect to other standard anti-depressants.

scholarly journals Improving Access to Psychological Therapies (IAPT) - The Need for Radical Reform

2018 ◽  
Vol 23 (9) ◽  
pp. 1136-1147 ◽  
Author(s):  
Michael J Scott
Keyword(s):  
Anxiety Disorders ◽  
Psychological Treatment ◽  
Structured Interview ◽  
Diagnostic Interview ◽  
Personal Injury ◽  
Depression And Anxiety ◽  
Modus Operandi ◽  
Radical Reform ◽  
Psychological Therapies ◽  
Treatment Of Depression

Improving Access to Psychological Therapies is a UK government-funded initiative to widen access to the psychological treatment of depression and anxiety disorders. The author has had the opportunity to independently assess 90 Improving Access to Psychological Therapies clients, using a standardised semi-structured interview, the Structured Clinical Diagnostic Interview for DSM Disorders (SCID) and to listen to their account of interaction with the service. The results suggest that only the tip of the iceberg fully recovers from their disorder (9.2%) whether or not they were treated before or after a personal injury claim. There is a pressing need to re-examine the modus operandi of the service.

scholarly journals Role of Depression and Anxiety Disorders in Takotsubo Syndrome: The Psychiatric Side of Broken Heart

Cureus ◽  
2020 ◽  
Author(s):  
Federico Oliveri ◽  
Harshit K Goud ◽  
Lubna Mohammed ◽  
Zainab Mehkari ◽  
Moiz Javed ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Takotsubo Syndrome ◽  
Depression And Anxiety

Non-Monoamine-Based Approach for the Treatment of Depression and Anxiety Disorders

2012 ◽  
Vol 1 (1) ◽  
pp. 1-27
Author(s):  
Shigeyuki Chaki ◽  
Taketoshi Okubo ◽  
Yoshinori Sekiguchi
Keyword(s):  
Anxiety Disorders ◽  
Depression And Anxiety ◽  
Treatment Of Depression

Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study

2009 ◽  
Vol 117 (1) ◽  
pp. 139-145 ◽  
Author(s):  
Shella Schirman ◽  
Sefi Kronenberg ◽  
Alan Apter ◽  
David Brent ◽  
Nadine Melhem ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Children And Adolescents ◽  
Depression And Anxiety ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Treatment Of Depression
Sign in / Sign up

Export Citation Format

Share Document